mitoxantrone has been researched along with Thrombopenia in 50 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To intensify a regimen of high-dose cyclophosphamide, mitoxantrone, and carboplatin that had previously produced high complete and overall response rates in metastatic breast cancer (MBC)." | 9.09 | Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer. ( Crump, M; Goss, P; Keating, A; MacKinnon, J; Nagy, T; Patnaik, A; Stewart, K, 2000) |
| "Mitoxantrone (MTZ) and vinorelbine (VNR) have shown a good efficacy in advanced breast cancer." | 9.08 | Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study. ( Comella, G; Comella, P; Cremone, L; Della Volpe, N; Frasci, G; Imbriani, A; Persico, G; Salzano, F, 1995) |
| "To assess efficacy and toxicity of less toxic analogs for advanced breast cancer in elderly women, we performed a phase II study using the combination mitoxantrone (MTZ)-vinorelbine (VNR)." | 9.08 | [A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women]. ( Bugat, R; Caunes, N; Chevreau, C; Gladieff, L; Houyau, P; Martinez, M; Mihura, J; Roché, H, 1996) |
| "Twenty-seven women with metastatic breast cancer were treated with mitoxantrone as a single agent, with the use of an intensive dose-escalating schedule." | 9.06 | Intensive single-agent mitoxantrone for metastatic breast cancer. ( Bhardwaj, S; Holland, JF; Jones, RB; Paciucci, PA; Shpall, EJ; Strashun, A; Wilfinger, CL, 1988) |
| "Mitoxantrone is highly efficacious in the treatment of severe multiple sclerosis (MS)." | 7.76 | [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia]. ( Ansorge, N; Chan, A; Dührsen, U; Gold, R; Meyer, C; Nückel, H; Ritter, PR; Salmen, S; Schmidt, WE; Siglienti, I; Stroet, A, 2010) |
| "46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks." | 7.68 | Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. ( Dalesio, O; Giaccone, G; Kirkpatrick, A; Mattson, K; Planteydt, HT; van Breukelen, FJ; van Zandwijk, N, 1991) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 7.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 6.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "All patients had advanced metastatic breast cancer and have been extensively pretreated with chemotherapy (28 patients), radiotherapy (13 patients), and hormonotherapy (24 patients)." | 6.68 | Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group. ( Panagos, GE, 1997) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 6.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| "Sixty-five patients with advanced breast carcinoma were treated with mitoxantrone, an anthracenedione with structural similarities to adriamycin." | 5.27 | Mitoxantrone: an active new agent in the treatment of advanced breast cancer. ( Bozek, T; Pavlidis, NA; Smith, IE; Stuart-Harris, RC, 1984) |
| "To intensify a regimen of high-dose cyclophosphamide, mitoxantrone, and carboplatin that had previously produced high complete and overall response rates in metastatic breast cancer (MBC)." | 5.09 | Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer. ( Crump, M; Goss, P; Keating, A; MacKinnon, J; Nagy, T; Patnaik, A; Stewart, K, 2000) |
| "Mitoxantrone (MTZ) and vinorelbine (VNR) have shown a good efficacy in advanced breast cancer." | 5.08 | Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study. ( Comella, G; Comella, P; Cremone, L; Della Volpe, N; Frasci, G; Imbriani, A; Persico, G; Salzano, F, 1995) |
| "To assess efficacy and toxicity of less toxic analogs for advanced breast cancer in elderly women, we performed a phase II study using the combination mitoxantrone (MTZ)-vinorelbine (VNR)." | 5.08 | [A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women]. ( Bugat, R; Caunes, N; Chevreau, C; Gladieff, L; Houyau, P; Martinez, M; Mihura, J; Roché, H, 1996) |
| "A comparison of patients receiving combination chemotherapy with mitomycin C, mitozantrone and methotrexate (3M) with and without tamoxifen for treatment of primary breast cancer indicates an increased risk of anaemia (P < 0." | 5.07 | A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. ( Ashley, SE; Luckit, J; Montes, A; O'Brien, ME; Powles, TJ; Treleaven, J, 1993) |
| "Twenty-seven women with metastatic breast cancer were treated with mitoxantrone as a single agent, with the use of an intensive dose-escalating schedule." | 5.06 | Intensive single-agent mitoxantrone for metastatic breast cancer. ( Bhardwaj, S; Holland, JF; Jones, RB; Paciucci, PA; Shpall, EJ; Strashun, A; Wilfinger, CL, 1988) |
| "Mitoxantrone is highly efficacious in the treatment of severe multiple sclerosis (MS)." | 3.76 | [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia]. ( Ansorge, N; Chan, A; Dührsen, U; Gold, R; Meyer, C; Nückel, H; Ritter, PR; Salmen, S; Schmidt, WE; Siglienti, I; Stroet, A, 2010) |
| "28 patients (26 with breast cancer and 2 with colon cancer) received mitomycin, mitoxantrone and methotrexate (MMM)." | 3.68 | Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate. ( Blomqvist, CP; Muhonen, TT; Pyrhönen, SO; Wiklund, TA, 1992) |
| "Twelve patients with relapsed or refractory malignant lymphoma were treated with IMV-triple P regimen consisting of ifosfamide (IFM), mitoxantrone (MIT), vindesine (VDS), pepleomycin (PEP), procarbazine (PCZ) and prednisolone (PDN)." | 3.68 | [Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma]. ( Arai, N; Hara, A; Shirai, T; Umeda, M, 1991) |
| "46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks." | 3.68 | Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. ( Dalesio, O; Giaccone, G; Kirkpatrick, A; Mattson, K; Planteydt, HT; van Breukelen, FJ; van Zandwijk, N, 1991) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 3.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "In patients with advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades." | 2.72 | Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell ly ( Dreyling, M; Hiddemann, W; Hoster, E; Lengfelder, E; Nickenig, C; Pfreundschuh, M; Reiser, M; Trumper, L; Unterhalt, M; Wandt, H, 2006) |
| " The maximal acceptable dosage of mitoxantrone was 10 mg/m2 x 2 due to serious hematologic toxicity." | 2.69 | Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. ( Berinstein, NL; Franssen, E; Haq, R; Sawka, CA, 1999) |
| " The study was designed to determine the safety and maximally tolerated dose of IV vinorelbine used in combination with a fixed dose of mitoxantrone for the treatment of patients with refractory solid tumors." | 2.69 | A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. ( Bigley, J; Burris, HA; Dieras, V; Eckardt, JR; Hardy, J; Hohneker, J; Jones, SF; Peacock, NW; Rodriguez, GI; Smith, L; Von Hoff, DD, 1998) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 2.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "All patients had advanced metastatic breast cancer and have been extensively pretreated with chemotherapy (28 patients), radiotherapy (13 patients), and hormonotherapy (24 patients)." | 2.68 | Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group. ( Panagos, GE, 1997) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 2.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| "Usually, thrombocytopenia was not associated with bleeding manifestations." | 2.45 | Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. ( Ben-Bassat, I; Bonstein, L; Gafter-Gvili, A; Raanani, P; Ram, R; Shpilberg, O, 2009) |
| "Myelosuppression with subsequent infections was the major toxicity of this regimen." | 1.28 | Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. ( del Valle, F; Dörken, B; Hiddemann, W; Ho, AD; Hunstein, W; Meusers, P; Rückle, H; Schlimok, G; Schwammborn, J; Thiel, E, 1989) |
| "Leukopenia was mild, moderate, severe (1,000-1,999/mm3), and life-threatening (less than 1,000/mm3) in 17%, 23%, 42%, and 2% of courses, respectively." | 1.28 | Phase II trial of mitoxantrone in head and neck carcinoma. ( Ardalan, B; Benedetto, P; Desai, P; Feun, LG; Hussein, AM; Richman, SP; Savaraj, N; Sridhar, KS; Waldman, SM, 1991) |
| "Sixty-five patients with advanced breast carcinoma were treated with mitoxantrone, an anthracenedione with structural similarities to adriamycin." | 1.27 | Mitoxantrone: an active new agent in the treatment of advanced breast cancer. ( Bozek, T; Pavlidis, NA; Smith, IE; Stuart-Harris, RC, 1984) |
| "Thirty-five patients with hepatocellular carcinoma (HCC) have been treated with the Anthracenedione derivative, Mitozantrone." | 1.27 | Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study. ( Dunk, AA; Johnson, PJ; Lok, AS; Melia, W; Murray-Lyon, I; Scott, SC; Thomas, HC; Williams, R, 1985) |
| "Thirty-seven patients with metastatic prostate cancer refractory to endocrine therapy were treated in a phase II trial of mitoxantrone." | 1.27 | Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. ( Crawford, ED; Drelichman, A; Osborne, CK; Von Hoff, DD, 1983) |
| "Mitoxantrone was administered by intravenous drip infusion of 12 mg/m2 every three weeks." | 1.27 | Phase II study of mitoxantrone in patients with non-small cell lung cancer. ( Eguchi, K; Hoshi, A; Saijo, N; Sakurai, M; Sano, T; Sasaki, Y; Shinkai, T; Suga, J; Tamura, T, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (26.00) | 18.7374 |
| 1990's | 23 (46.00) | 18.2507 |
| 2000's | 10 (20.00) | 29.6817 |
| 2010's | 4 (8.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrisqueta, P | 1 |
| Villamor, N | 1 |
| Terol, MJ | 1 |
| González-Barca, E | 1 |
| González, M | 1 |
| Ferrà, C | 1 |
| Abella, E | 1 |
| Delgado, J | 1 |
| García-Marco, JA | 1 |
| González, Y | 1 |
| Carbonell, F | 1 |
| Ferrer, S | 1 |
| Monzó, E | 1 |
| Jarque, I | 1 |
| Muntañola, A | 1 |
| Constants, M | 1 |
| Escoda, L | 1 |
| Calvo, X | 1 |
| Bobillo, S | 1 |
| Montoro, JB | 1 |
| Montserrat, E | 1 |
| Bosch, F | 1 |
| Ram, R | 1 |
| Bonstein, L | 1 |
| Gafter-Gvili, A | 1 |
| Ben-Bassat, I | 1 |
| Shpilberg, O | 1 |
| Raanani, P | 1 |
| Godley, LA | 1 |
| Njiaju, UO | 1 |
| Green, M | 1 |
| Weiner, H | 1 |
| Lin, S | 1 |
| Odenike, O | 1 |
| Rich, ES | 1 |
| Artz, A | 1 |
| Van Besien, K | 1 |
| Daugherty, CK | 1 |
| Zhang, Y | 1 |
| Le Beau, MM | 1 |
| Stock, W | 1 |
| Larson, RA | 1 |
| Meyer, C | 1 |
| Ansorge, N | 1 |
| Siglienti, I | 1 |
| Salmen, S | 1 |
| Stroet, A | 1 |
| Nückel, H | 1 |
| Dührsen, U | 1 |
| Ritter, PR | 1 |
| Schmidt, WE | 1 |
| Gold, R | 1 |
| Chan, A | 1 |
| Staib, P | 1 |
| Forsch, S | 1 |
| Niedeggen, A | 1 |
| Janssens, U | 1 |
| Chamorey, E | 1 |
| Gressin, R | 1 |
| Peyrade, F | 1 |
| Rossi, JF | 1 |
| Lepeu, G | 1 |
| Foussard, C | 1 |
| Harrousseau, JL | 1 |
| Fabbro, M | 1 |
| Richard, B | 1 |
| Delwail, V | 1 |
| Maisonneuve, H | 1 |
| Vilque, JP | 1 |
| Thyss, A | 1 |
| Nickenig, C | 1 |
| Dreyling, M | 1 |
| Hoster, E | 1 |
| Pfreundschuh, M | 1 |
| Trumper, L | 1 |
| Reiser, M | 1 |
| Wandt, H | 1 |
| Lengfelder, E | 1 |
| Unterhalt, M | 1 |
| Hiddemann, W | 3 |
| Lü, SQ | 1 |
| Yang, JM | 1 |
| Song, XM | 1 |
| Chen, L | 1 |
| Zhang, WP | 1 |
| Ni, X | 1 |
| Xu, XQ | 1 |
| Wang, JM | 1 |
| Errante, D | 1 |
| Bianco, A | 1 |
| Aversa, SML | 1 |
| Salvagno, L | 1 |
| Valdivieso, M | 2 |
| Umsawasdi, T | 1 |
| Spitzer, G | 1 |
| Chiuten, DF | 1 |
| Booser, DJ | 1 |
| Dhingra, HM | 1 |
| Bodey, GP | 2 |
| Mattox, DE | 1 |
| Clark, GM | 1 |
| Balcerzak, SP | 1 |
| O'Bryan, RM | 1 |
| Oishi, N | 1 |
| Stuckey, WJ | 1 |
| Loesch, DM | 1 |
| Von Hoff, DD | 3 |
| Kuhn, J | 1 |
| Coltman, CA | 1 |
| Tio, F | 1 |
| Chaudhuri, TK | 1 |
| Bender, JF | 1 |
| Grillo-Lopez, AJ | 1 |
| Osborne, CK | 1 |
| Drelichman, A | 1 |
| Crawford, ED | 1 |
| Stuart-Harris, RC | 1 |
| Bozek, T | 1 |
| Pavlidis, NA | 1 |
| Smith, IE | 1 |
| Bedikian, AY | 1 |
| Stroehlein, J | 1 |
| Korinek, J | 1 |
| Karlin, D | 1 |
| Anderson, KC | 1 |
| Cohen, GI | 1 |
| Garnick, MB | 1 |
| Avilés, A | 1 |
| Guzmán, R | 1 |
| Talavera, A | 1 |
| García, EL | 1 |
| Díaz-Maqueo, JC | 1 |
| Frasci, G | 1 |
| Comella, G | 1 |
| Comella, P | 1 |
| Salzano, F | 1 |
| Cremone, L | 1 |
| Della Volpe, N | 1 |
| Imbriani, A | 1 |
| Persico, G | 1 |
| Patrone, F | 1 |
| Ballestrero, A | 1 |
| Ferrando, F | 1 |
| Brema, F | 1 |
| Moraglio, L | 1 |
| Valbonesi, M | 1 |
| Basta, P | 1 |
| Ghio, R | 1 |
| Gobbi, M | 1 |
| Sessarego, M | 1 |
| Damon, LE | 1 |
| Rugo, HS | 1 |
| Ries, CA | 1 |
| Linker, CA | 1 |
| Colleoni, M | 1 |
| Buzzoni, R | 1 |
| Bajetta, E | 1 |
| Bochicchio, AM | 1 |
| Bartoli, C | 1 |
| Audisio, R | 1 |
| Bonfanti, G | 1 |
| Nolè, F | 1 |
| Carmo-Pereira, J | 1 |
| Costa, FO | 1 |
| Henriques, E | 1 |
| Montes, A | 1 |
| Powles, TJ | 1 |
| O'Brien, ME | 1 |
| Ashley, SE | 1 |
| Luckit, J | 1 |
| Treleaven, J | 1 |
| Beuzeboc, P | 1 |
| Pierga, JY | 1 |
| Lyonnet, DS | 1 |
| Couturier, J | 1 |
| Pouillart, P | 1 |
| Gladieff, L | 1 |
| Houyau, P | 1 |
| Mihura, J | 1 |
| Martinez, M | 1 |
| Caunes, N | 1 |
| Chevreau, C | 1 |
| Bugat, R | 1 |
| Roché, H | 1 |
| Panagos, GE | 1 |
| Ingle, JN | 1 |
| Kardinal, CG | 1 |
| Suman, VJ | 1 |
| Veeder, MH | 1 |
| Schaefer, PL | 1 |
| Kirschling, RJ | 1 |
| Mailliard, JA | 1 |
| Wang, WS | 1 |
| Tzeng, CH | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Hsieh, RK | 1 |
| Yen, CC | 1 |
| Chen, PM | 1 |
| Peacock, NW | 1 |
| Burris, HA | 1 |
| Dieras, V | 1 |
| Smith, L | 1 |
| Rodriguez, GI | 1 |
| Eckardt, JR | 1 |
| Jones, SF | 1 |
| Hardy, J | 1 |
| Hohneker, J | 1 |
| Bigley, J | 1 |
| Navarro, JT | 1 |
| Hernández, JA | 1 |
| Ribera, JM | 1 |
| Sancho, JM | 1 |
| Oriol, A | 1 |
| Pujol, M | 1 |
| Millá, F | 1 |
| Feliu, E | 1 |
| Kakolyris, S | 1 |
| Kourousis, C | 1 |
| Koukourakis, M | 1 |
| Androulakis, N | 1 |
| Vamvakas, L | 1 |
| Agelaki, S | 1 |
| Hatzidaki, D | 1 |
| Samonis, G | 1 |
| Tsiftsis, D | 1 |
| Georgoulias, V | 1 |
| Haq, R | 1 |
| Sawka, CA | 1 |
| Franssen, E | 1 |
| Berinstein, NL | 1 |
| Sternberg, DW | 1 |
| Aird, W | 1 |
| Neuberg, D | 1 |
| Thompson, L | 1 |
| MacNeill, K | 1 |
| Amrein, P | 1 |
| Shulman, LN | 1 |
| Patnaik, A | 1 |
| MacKinnon, J | 1 |
| Goss, P | 1 |
| Nagy, T | 1 |
| Stewart, K | 1 |
| Keating, A | 1 |
| Crump, M | 1 |
| Pérez-Gracia, JL | 1 |
| Colomer, R | 1 |
| Esteban, E | 1 |
| Barceló, R | 1 |
| Benavides, M | 1 |
| Puertas, J | 1 |
| Arcediano, A | 1 |
| Tornamira, MV | 1 |
| Valentín, V | 1 |
| Muñoz, A | 1 |
| Cortés-Funes, H | 1 |
| Hornedo, J | 1 |
| Siemens, HJ | 1 |
| Gerke, P | 1 |
| Steinhoff, J | 1 |
| Roth-Isigkeit, A | 1 |
| Wagner, K | 1 |
| Brückner, S | 1 |
| Levine, EG | 1 |
| Halabi, S | 1 |
| Roberts, JD | 1 |
| Kaplan, EB | 1 |
| Rago, R | 1 |
| Atkins, JN | 1 |
| Vogelzang, NJ | 1 |
| Aitini, E | 1 |
| Cavazzini, G | 1 |
| Cantore, M | 1 |
| Rabbi, C | 1 |
| Rivera, A | 1 |
| Togliani, B | 1 |
| Di Marco, A | 1 |
| Smerieri, F | 1 |
| Muhonen, TT | 1 |
| Wiklund, TA | 1 |
| Blomqvist, CP | 1 |
| Pyrhönen, SO | 1 |
| Sridhar, KS | 1 |
| Hussein, AM | 1 |
| Benedetto, P | 1 |
| Waldman, SM | 1 |
| Feun, LG | 1 |
| Savaraj, N | 1 |
| Richman, SP | 1 |
| Ardalan, B | 1 |
| Desai, P | 1 |
| Arai, N | 1 |
| Hara, A | 1 |
| Umeda, M | 1 |
| Shirai, T | 1 |
| van Breukelen, FJ | 1 |
| Mattson, K | 1 |
| Giaccone, G | 1 |
| van Zandwijk, N | 1 |
| Planteydt, HT | 1 |
| Kirkpatrick, A | 1 |
| Dalesio, O | 1 |
| Samonigg, H | 1 |
| Stöger, H | 1 |
| Kasparek, AK | 1 |
| Schmid, M | 1 |
| Dusleag, J | 1 |
| Pfeiffer, K | 1 |
| Smola, M | 1 |
| Steindorfer, P | 1 |
| Lechner, P | 1 |
| Essink, ME | 1 |
| von Eiff, M | 1 |
| Büchner, T | 1 |
| van de Loo, J | 1 |
| Ho, AD | 1 |
| del Valle, F | 1 |
| Rückle, H | 1 |
| Schwammborn, J | 1 |
| Schlimok, G | 1 |
| Meusers, P | 1 |
| Thiel, E | 1 |
| Dörken, B | 1 |
| Hunstein, W | 1 |
| Yoshida, T | 1 |
| Okazaki, N | 1 |
| Yoshino, M | 1 |
| Ohkura, H | 1 |
| Miyamoto, K | 1 |
| Shimada, Y | 1 |
| Dunk, AA | 1 |
| Scott, SC | 1 |
| Johnson, PJ | 1 |
| Melia, W | 1 |
| Lok, AS | 1 |
| Murray-Lyon, I | 1 |
| Williams, R | 1 |
| Thomas, HC | 1 |
| Shpall, EJ | 1 |
| Jones, RB | 1 |
| Holland, JF | 1 |
| Bhardwaj, S | 1 |
| Paciucci, PA | 1 |
| Wilfinger, CL | 1 |
| Strashun, A | 1 |
| Suga, J | 1 |
| Saijo, N | 1 |
| Shinkai, T | 1 |
| Eguchi, K | 1 |
| Sasaki, Y | 1 |
| Sakurai, M | 1 |
| Sano, T | 1 |
| Tamura, T | 1 |
| Hoshi, A | 1 |
| Falkson, G | 1 |
| Coetzer, BJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Exploring Patient Engagement Patterns and Participation Trends in Mantle Cell Lymphoma Clinical Trials[NCT06049472] | 500 participants (Anticipated) | Observational | 2024-10-31 | Not yet recruiting | |||
| A Phase II Trial of Adjuvant Mitoxantrone (NSC #301739) for High Risk Patients Following Radical Prostatectomy[NCT00003858] | Phase 2 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to The study was not activated.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mitoxantrone and Thrombopenia
| Article | Year |
|---|---|
Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].
Topics: Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B | 1996 |
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administr | 1997 |
22 trials available for mitoxantrone and Thrombopenia
| Article | Year |
|---|---|
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Area U | 2013 |
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2010 |
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free | 2005 |
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell ly
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclopho | 2006 |
Randomized study for the treatment of adult advanced Hodgkin's disease: epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD).
Topics: Actuarial Analysis; Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protoco | 1994 |
Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1995 |
Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modal | 1995 |
A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Administration Schedule | 1993 |
Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1993 |
A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interact | 1993 |
[A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 1996 |
Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; | 1997 |
Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1997 |
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administr | 1997 |
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male | 1998 |
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplas | 1999 |
Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; D | 1999 |
Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cy | 2000 |
High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; G | 2001 |
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Drug Resista | 2002 |
A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 1992 |
Intensive single-agent mitoxantrone for metastatic breast cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Female; Humans; Leukopenia; Mitoxantrone; N | 1988 |
26 other studies available for mitoxantrone and Thrombopenia
| Article | Year |
|---|---|
[Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].
Topics: Adult; Analgesics; Humans; Leukemia; Male; Mitoxantrone; Multiple Sclerosis; Thrombocytopenia | 2010 |
[Percutaneous coronary intervention in a patient with acute myeloid leukemia].
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; | 2012 |
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexa | 2007 |
Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.
Topics: Administration, Oral; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ble | 2008 |
Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anthraquinones; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma | 1984 |
Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Femal | 1984 |
Phase I investigation of ametantrone.
Topics: Aged; Anthraquinones; Arrhythmias, Cardiac; Bone Marrow; Dose-Response Relationship, Drug; Drug Eval | 1983 |
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Anthraquinones; Drug Evaluation; Humans; Leukopenia; Male; Middle Aged; Mitoxa | 1983 |
Mitoxantrone: an active new agent in the treatment of advanced breast cancer.
Topics: Adult; Aged; Agranulocytosis; Anthraquinones; Breast Neoplasms; Doxorubicin; Drug Evaluation; Female | 1984 |
Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukocyte Count | 1983 |
Phase II trial of mitoxantrone.
Topics: Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Heart; | 1982 |
Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1994 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Com | 2000 |
A prolonged APTT in a patient with a low grade malignant NHL - a case report.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Coagulation Factors; C | 2002 |
Unexpected prolonged myelosuppression after mitomycin, mitoxantrone and methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Fe | 1992 |
Phase II trial of mitoxantrone in head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Adenoid Cystic; Carcinoma, Squamous Cell; Dose-Response R | 1991 |
[Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Female; Hea | 1991 |
Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Mitoxantr | 1991 |
Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distributi | 1991 |
Effect of antifungal therapy on hematological recovery after intensive antileukemic chemotherapy.
Topics: Agranulocytosis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun | 1990 |
Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation | 1989 |
Phase II trial of mitoxantrone in patients with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Drug Evaluation; Female; Humans; Leukopenia; Liver Neoplasms; Male; | 1988 |
Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study.
Topics: Adult; Aged; Anthraquinones; Carcinoma, Hepatocellular; Child; Drug Evaluation; Female; Heart Diseas | 1985 |
Phase II study of mitoxantrone in patients with non-small cell lung cancer.
Topics: Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Heart; Humans; Leukopenia; Lun | 1986 |
Phase II studies of mitoxantrone in patients with primary liver cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Humans; Leukopenia; Liver Neopl | 1985 |